Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)

NCT03790852 is registered in ClinicalTrials.gov with Kodiak Sciences Inc as lead sponsor.

NCT NCT03790852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03790852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Lead sponsor
Kodiak Sciences Inc
Phase
Phase 1
Overall status
Terminated
Start date
December 26, 2018
Completion date
June 9, 2022
Enrollment
121 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, retinal vein occlusion, wet age-related macular degeneration